Home People Michael Fowler – Biography, Age, Medical Education, Career & Net Worth

Michael Fowler – Biography, Age, Medical Education, Career & Net Worth

Michael Fowler (born May 6, 1951) is a board-certified American cardiologist in Stanford, California.

Dr. Michael Fowler is a Professor of Cardiovascular Medicine at Stanford Hospital & Clinics.

Michael Fowler

Michael Fowler Facts

  • Full Name: Michael B. Fowler
  • Age: 71 years old
  • Date of Birth: May 6, 1951
  • Place of Birth: London, England
  • Occupation: Cardiologist
  • Nationality: American

Michael Fowler Medical School & Residency

  • Charing Cross and Westminister Medical School – Medical School

Michael Fowler Career

Dr. Fowler attended the Charing Cross Hospital Medical School, London, England. He has been elected to be a fellow in the Royal College of Physicians. He came to Stanford University on a British Heart Foundation, American Heart Association reciprocal fellowship award.

Dr. Fowler was appointed to the faculty in 1982. He is former Medical Director of the Heart Failure Program at Stanford University School of Medicine and Medical Director of the Stanford Cardiomyopathy Center.

Dr. Fowler has specialized in the treatment and research related to heart failure for over 35 years. He played an important role in the development of beta blocking drugs to treat heart failure and has also participated in most and the major studies that have led to our current comprehensive treatment for heart failure with drugs and devices.

He is an expert in evaluating patients who may benefit from cardiac transplantation or mechanical support therapy.

Hospital Affiliations

  • Stanford Health Care-Stanford Hospital, Stanford, CA

Specialty Expertise

Dr. Michael B Fowler has the following 13 areas of expertise

  • High Cholesterol
  • Heart Attack
  • Arrhythmia
  • High Cholesterol (Hypercholesterolemia)
  • Blood Clot
  • Hypertension
  • Atherosclerosis
  • Unstable Angina
  • Stroke
  • Heart Failure
  • Heart Block
  • Heart Diseases
  • Acute Coronary Syndrome (ACS)

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • Aetna HMO Deductible Plan CA only
  • Aetna Managed Choice POS Open Access
  • Aetna Signature Administrators PPO
  • BCBS Blue Card PPO
  • Blue Cross CA PPO Prudent Buyer Small Group
  • Blue Cross CA Advantage PPO Preferred DirectAccess Plus
  • Blue Cross CA PPO Prudent Buyer Individual
  • Blue Cross CA PPO Prudent Buyer Large Group
  • Blue Cross CA Select PPO
  • Blue Shield CA Access Plus HMO
  • Blue Shield CA Access Plus Savenet
  • Blue Shield CA Bronze Full PPO 4500
  • Blue Shield CA Local Access Plus HMO
  • Blue Shield CA Platinum Access+ HMO 25
  • Blue Shield CA Platinum Local Access + HMO 25
  • Blue Shield CA PPO
  • CIGNA LocalPlus
  • CIGNA Open Access Plus
  • First Health PPO
  • Health Net CA Individual and Family PPO
  • Health Net CA PPO
  • Health Net PureCare HSP Individual and Family Plans
  • Health Net PureCare One EPO Individual & Family Plan
  • Humana Choice POS
  • Multiplan PPO
  • PHCS PPO Kaiser
  • UHC Choice Plus POS
  • UHC Options PPO
  • UHC West SignatureValue Advantage HMO Value Network
  • UHC West SignatureValue HMO

Location & Contact Information

Stanford Hospital Cardiovascular Medicine Clinic
300 Pasteur Dr Ste A260
Stanford, CA 94305
(650) 723-6459

Fax: (650) 072-3839
Website: StanfordHealthCare.org

Richard B D Chun MD
1101 Smith Ln
Roseville, CA 95661
(916) 783-7118

Fax:(916) 679-7034

Expert Publications

Data provided by the National Library of Medicine

  • Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure.
  • Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
  • Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
  • NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
  • Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
  • Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure.
  • Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link.
  • Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
  • Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
  • B-type natriuretic peptide is effective therapy before care.
  • Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
  • The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.
  • Cardiomyopathy of insulin resistance.
  • Why do we need to prevent right ventricular pacing?
  • Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial.

Michael Fowler Net Worth

Michael Fowler has an estimated net worth of $5 million.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.